Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
75.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Analyst Expectations For Ionis Pharmaceuticals's Future
↗
June 12, 2025
Via
Benzinga
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
June 12, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
June 11, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 14 Analysts
↗
May 20, 2025
Via
Benzinga
Earnings Scheduled For April 30, 2025
↗
April 30, 2025
Via
Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
↗
March 11, 2025
Via
Benzinga
What Analysts Are Saying About Ionis Pharmaceuticals Stock
↗
February 20, 2025
Via
Benzinga
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 19, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to host 2025 virtual Annual Meeting of Stockholders
May 06, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 13 Experts
↗
May 01, 2025
Via
Benzinga
Earnings Scheduled For February 19, 2025
↗
February 19, 2025
Via
Benzinga
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge
↗
April 30, 2025
Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new and existing drug products.
Via
Benzinga
Ionis reports first quarter 2025 financial results
April 30, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
April 29, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to hold first quarter 2025 financial results webcast
April 16, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'
↗
April 07, 2025
HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical milestones ahead.
Via
Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
April 07, 2025
Via
Benzinga
Ionis to host expert panel discussion on sHTG
April 03, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
↗
March 31, 2025
Via
Benzinga
Ionis to present at upcoming investor conferences
March 31, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Competitive Analysis In The ATTR-CM Field
↗
March 30, 2025
Precision medicine was proved in the ATTR-CM field. We think acoramidis is a more potent TTR stabilizer and that it will attract first-line patients. Tafamidis, acoramidis and vutrisiran will share the...
Via
Talk Markets
Topics
Stocks / Equities
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
March 26, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
↗
March 12, 2025
Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Via
Benzinga
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
March 11, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
March 10, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis to present at upcoming investor conferences
February 25, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
February 20, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
Ionis Pharma Beats Expectations for Q4
↗
February 19, 2025
The biotech outperformed expectations with better-than-expected revenue and a smaller-than-expected loss.
Via
The Motley Fool
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
↗
February 19, 2025
Ionis Pharmaceuticals posted a smaller-than-expected Q4 loss and exceeded revenue estimates. The company projects 2025 revenue of over $600 million.
Via
Benzinga
Ionis reports fourth quarter and full year 2024 financial results
February 19, 2025
From
Ionis Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
